Search
Cart 0 / $0.00

Smart Contact Lenses Business Insights

How Much Capital Does Smart Contact Lens Development Really Need?

A smart contact lens company is not funded like a small eyewear shop. It is closer to a regulated medical-device platform with optics, microelectronics, biocompatible materials, software, clinical validation, and a manufacturing transfer plan all moving at the same time. The business may eventually sell a lens, a companion wearable, a reader, or a subscription, but the first financial question is simpler: how much cash is required before the product is credible enough for regulators, clinicians, strategic partners, and investors?

In the U.S., the planning baseline should start with two facts. Contact lenses are medical devices in the FDA system, and the CDC estimates that about 45 million people in the United States wear contact lenses when they are cared for properly and used safely through normal eye-care channels. Those two facts create opportunity, but they also create cost: a device that sits on the eye has to clear a much higher evidence bar than a normal wearable accessory. Review the FDA's consumer page on contact lenses as medical devices and the CDC's contact lens safety overview before treating market size as near-term revenue.

$2.9M-$18.5M Pre-authorization planning range A practical assumption range for prototype, testing, quality, regulatory, pilot manufacturing, and early clinical work.
24-60 months Cash runway to first serious market decision Shorter for sensor-only prototypes, longer for display, drug-delivery, or high-risk therapeutic claims.
0 revenue Common early-stage reality Pilot payments may help, but they rarely cover the full burn before product authorization and repeatable manufacturing.

The range is wide because the phrase “smart contact lens” can mean very different products. A pressure-sensing lens for glaucoma monitoring, a tear biomarker sensor, a drug-delivery lens, and an augmented-vision display lens do not share the same regulatory pathway, electronics architecture, clinical endpoints, or manufacturing risk. A founder should build the first model around the intended use, not the product label.

Investment category Practical U.S. planning range What the money is buying Financial planning note
IP strategy, freedom-to-operate, entity setup $50,000-$250,000 Patent searches, provisional and utility filings, licensing review, founder agreements, confidentiality systems Underfunding IP can make later licensing or strategic investment harder.
Lens, sensor, electronics, and optics prototypes $300,000-$1.5M Materials testing, embedded components, antenna or power tests, benchtop prototypes, firmware, early design iterations Iteration cycles are the real cost; one successful lab prototype is not a manufacturable product.
Lab setup, cleanroom access, metrology, test equipment $250,000-$1.2M Benches, optical measurement, sterilization validation access, contract cleanroom runs, calibration, environmental controls Using a university or contract facility can reduce capex but may slow scheduling.
Biocompatibility, bench, stability, electrical, and software testing $400,000-$2.0M Safety tests, extractables and leachables work, accuracy testing, environmental stress, packaging, shelf-life, cybersecurity documentation Failed tests often create redesign expense, not just retest expense.
Quality system and design controls $150,000-$600,000 Design history file, risk management, supplier controls, document control, complaint readiness, audits This is a core operating system, not paperwork to add at the end.
Regulatory strategy and submission preparation $125,000-$700,000 Pre-submission meetings, predicate analysis, De Novo or PMA strategy, technical writing, labeling, user-fee planning Wrong pathway assumptions can add years and millions to the plan.
Pilot manufacturing, tooling, fixtures, validation lots $500,000-$3.0M Process development, molds, flexible electronics integration, inspection, packaging, lot traceability, supplier qualification Yield losses can consume cash before any product is saleable.
Early clinical study and investigator support $750,000-$5.0M Protocol, IRB, investigator sites, monitoring, data management, devices for study use, safety reporting Clinical cash needs depend heavily on endpoints, sample size, follow-up, and risk category.
Launch working capital and market access preparation $400,000-$4.25M Inventory, warranty reserves, training, optometry channel education, payer or hospital validation, first commercial hires Approval does not equal cash collection; launch inventory and channel education still need funding.
Total planning range $2.925M-$18.5M Pre-commercial development plus early launch readiness Use staged financing gates instead of assuming the full amount is raised on day one.
Typical pre-commercial capital mix Takeaway: clinical, pilot manufacturing, and working capital can dominate the budget after the prototype looks promising.
Clinical study and investigator work 27%
Launch working capital 23%
Pilot manufacturing and validation 16%
Prototype engineering 14%
Bench and safety testing 11%
Quality, IP, regulatory setup 9%

What Monthly Burn Rate Should Founders Model Before Revenue?

The operating model should be built around monthly burn, not monthly sales, until the company has authorization, validated manufacturing, and signed commercial channels. Payroll, prototype fabrication, quality documentation, clinical planning, and external testing create a cash clock that does not stop just because a pilot site is delayed.

The largest recurring cost is specialized labor. A lean team may still need optics or materials engineering, embedded electronics, firmware, medical-device software, quality, regulatory, clinical operations, and founder-level product leadership. The BLS Occupational Employment and Wage Statistics tables are useful for salary benchmarking, but the actual cost should be loaded for payroll taxes, benefits, recruiting fees, consultants, and equity compensation expectations. In many U.S. hubs, a realistic fully loaded technical headcount budget can run 1.25x-1.45x base salary.

Monthly operating cost Lean R&D stage Clinical-ready stage Why it matters
Technical payroll and founders $150,000 $450,000 Engineering velocity controls prototype maturity and investor milestones.
Quality, regulatory, and clinical operations $35,000 $140,000 Design history, risk files, protocol work, and monitoring must be budgeted early.
Lab, cleanroom access, rent, and facilities $20,000 $150,000 Facility choices determine capex, scheduling, contamination risk, and supplier dependence.
Prototype fabrication and materials $50,000 $300,000 Miniaturized components, failed lots, and repeat builds can create volatile monthly spend.
Software, cloud, data security, and test systems $15,000 $80,000 Connected lenses may need secure data pipelines, device logs, and validation environments.
External consultants, CROs, and specialty labs $25,000 $180,000 Use contractors for narrow expertise, but model retainer and change-order risk.
Legal, IP, finance, insurance, and administration $50,000 $160,000 Board reporting, audits, product liability planning, and patent work scale with financing rounds.
Business development, clinician education, and KOL work $20,000 $120,000 Adoption depends on clinician trust long before mass-market promotion starts.
Estimated monthly burn $365,000 $1.58M A 24-month plan at these levels implies roughly $8.8M-$37.9M before financing cushion.
Monthly burn mix at clinical-ready stage Takeaway: payroll is large, but prototype, facilities, and outside experts can make the burn rate lumpy. Technical payroll and founders: 39% Prototype fabrication and materials: 13% Facilities and cleanroom access: 14% Consultants, CROs, and specialty labs: 12% Quality, regulatory, clinical operations: 12% Software, G&A, and market education: 10%

The practical one-liner: a smart contact lens team can look efficient on a headcount chart and still burn cash quickly because the product requires repeated physical builds, regulated documentation, and specialized testing.

Which Regulatory Path Changes the Economics the Most?

Regulatory pathway is one of the biggest financial assumptions in the model. A simple lens with an incremental feature may have a different path from a novel sensor or display lens with no clear predicate. The FDA's De Novo classification pathway is designed for certain novel devices where general or special controls can provide reasonable assurance of safety and effectiveness, while the IDE framework governs investigational use when clinical data are needed for safety and effectiveness.

The regulatory cost is not only the FDA fee. The bigger cost is evidence. A submission that needs more biocompatibility data, usability testing, software validation, cybersecurity documentation, shelf-life evidence, clinical endpoints, or manufacturing controls changes payroll, consultant budgets, clinical trial spend, and runway.

Regulatory planning item Known or modelable cost Cash-flow effect Planning implication
FY 2026 FDA establishment registration $11,423 annual fee Recurring compliance cost once registration is required Small-business reductions generally do not reduce the establishment fee.
510(k) submission fee $26,067 standard; $6,517 small business Lower direct fee, but only useful if predicate and evidence strategy fit A forced 510(k) assumption can be dangerous if the device is genuinely novel.
De Novo request fee $173,782 standard; $43,446 small business Higher fee and typically more evidence preparation than a straightforward 510(k) Common planning case for a novel moderate-risk smart lens concept.
PMA, PDP, PMR, or BLA fee $579,272 standard; $144,818 small business Direct fee is meaningful, but clinical and manufacturing evidence are usually much larger High-risk claims can move the model from venture-scale to major strategic-capital scale.
Quality management system $150,000-$600,000 setup assumption Adds documentation, audits, supplier controls, and quality headcount Budget it before clinical devices are built, not after.
Connected-device cybersecurity documentation $75,000-$400,000 planning assumption Adds secure architecture, threat modeling, vulnerability handling, and submission content For connected lenses, software evidence can slow the launch just as much as lens hardware.

FDA's FY 2026 medical-device user-fee page lists the establishment fee and submission fees, including 510(k), De Novo, and PMA amounts, and it explains when small-business reductions may apply through the SBD program. The FDA fee table should be a direct input in the regulatory budget rather than an afterthought.

Common modeling mistake Do not model FDA fees as the main regulatory expense. The larger financial exposure is the cost of generating evidence, responding to deficiencies, maintaining quality records, and keeping the team funded while the review clock and clinical milestones move.

The company also needs to model the current quality environment. FDA's Quality Management System Regulation page explains that FDA began using the updated inspection process aligned with QMSR on February 2, 2026, and FDA's cybersecurity guidance explains the submission content expected for devices with cybersecurity risk. For a lens that collects data, communicates wirelessly, or connects to a mobile application, both the QMSR operating model and medical-device cybersecurity planning belong inside the base case.

How Does a Smart Contact Lens Company Earn Revenue?

Revenue should be modeled by use case, channel, and reimbursement logic. A lens that helps monitor intraocular pressure may sell through ophthalmology or specialty eye-care channels. A tear-biomarker sensor may need clinical validation and payer logic. A vision-assistance display lens may begin with a narrow medical or enterprise use case before broader consumer positioning is realistic. A disposable smart lens without recurring data value behaves differently from a hardware-plus-software platform.

There is also a channel issue. Contact lens adoption normally involves an eye-care professional, fitting, prescription, patient education, and follow-up. The startup may receive wholesale revenue while the patient-facing price includes professional services and channel margin. That means gross sales, net revenue, and patient cost are different numbers.

Lens packs Companion reader Monitoring subscription Clinical dashboard Enterprise pilot Licensing or strategic partnership
Revenue unit Planning price assumption What drives volume Margin sensitivity
Smart lens pack or replacement cycle $100-$400 per active user per month at gross patient value; lower net revenue after channel deductions Clinical need, comfort, prescription workflow, replacement frequency, and patient adherence Yield, scrap, packaging, sterilization, returns, and channel margin.
Reader, charging accessory, or companion wearable $500-$2,000 one-time gross price assumption Whether the system needs power, data transfer, display processing, or clinician setup Electronics BOM, warranty, fulfillment, field failures, and replacement cycles.
Software or monitoring subscription $15-$100 per active user per month Data usefulness, clinician workflow, patient engagement, and billing path Cloud, support, privacy, security, and ongoing validation.
Clinic, hospital, or research pilot $50,000-$300,000 per site or study collaboration Clinical partner interest, unmet need, protocol strength, and available devices Pilots can validate demand but may require heavy support and custom reporting.
Technology license or strategic supply agreement Milestones, royalties, or minimum purchases; highly deal-specific Patent strength, manufacturability, regulatory clarity, and strategic fit May reduce go-to-market cost but cap upside or shift control to a partner.
Revenue planning rule Model three prices for every unit: gross patient or enterprise price, net company revenue after channel margin, and contribution margin after direct manufacturing, warranty, fulfillment, data, and support costs.

For comparable scale economics, established contact-lens and eye-care companies show why a startup should not confuse high gross margin potential with easy profitability. CooperCompanies reported a fourth-quarter fiscal 2025 gross margin of 61% and a non-GAAP gross margin of 66%, while its CooperVision segment generated $709.6 million of quarterly revenue. Alcon's 2025 annual report shows $990 million of research and development expense. These are not direct startup benchmarks, but CooperCompanies' margin disclosure and Alcon's R&D disclosure show the scale needed to absorb manufacturing, product launches, regulatory work, and portfolio development.

Break-Even Depends on Active Wearers, Yield, and Net Revenue

Break-even should be calculated on net revenue and contribution margin, not on the sticker price a patient might pay. The founder needs to model how much of the patient or clinic price reaches the company after distributor margin, eye-care channel economics, returns, warranty, service, and payer or contracting discounts.

Break-even formula break-even revenue = fixed operating costs divided by contribution margin If annual fixed operating costs are $12.0M and contribution margin is 55%, the company needs about $21.8M of net revenue before it covers operating costs. If net annual revenue is $750 per active wearer, that means roughly 29,100 active wearers before operating profit turns positive.

The hardest part is not the formula. The hard part is choosing inputs that reflect adoption friction. A product may be technically impressive, but active-wearer volume depends on clinician recommendation, comfort, safety profile, wear time, replacement frequency, prescription workflow, patient willingness to pay, and whether the device solves a problem that is urgent enough to change behavior.

$22.2M Conservative break-even net revenue $10.0M of fixed cost divided by a 45% contribution margin. At $750 of net annual revenue per active wearer, this implies about 29,600 active wearers.
$21.8M Base-case break-even net revenue $12.0M of fixed cost divided by a 55% contribution margin. The active-wearer count is about 29,100 if net annual revenue is $750.
$24.6M Upside manufacturing break-even Even at a 65% contribution margin, a larger $16.0M operating platform needs about 32,800 active wearers at the same net annual revenue.
Gross margin levers Improve fabrication yield, reduce electronics BOM, qualify secondary suppliers, lower scrap, improve packaging throughput, and reduce warranty replacements.
Volume levers Increase active prescribers, reduce fitting friction, improve wear comfort, lift patient retention, secure payer or enterprise support, and shorten reorder cycles.

A useful break-even model should include a sensitivity tab for price, active users, gross margin, yield, and operating expense. A one-point gross margin improvement matters less when revenue is $1M; it matters a lot when the company is shipping tens of thousands of monthly replacement cycles.

What KPIs Decide Whether the Model Is Working?

The KPI dashboard should track technical feasibility, regulatory readiness, manufacturing economics, adoption, and cash runway together. A smart lens company can fail with excellent clinical interest if manufacturing yield is poor. It can also fail with good prototypes if wearer comfort, sensor accuracy, data reliability, or clinician workflow does not support repeat use.

KPI Formula or calculation Planning benchmark or interpretation Model connection
Prototype build yield Functional prototypes divided by total builds Early R&D may be below 30%; pilot manufacturing should show a rising trend toward commercial repeatability Drives unit cost, scrap, testing spend, and launch inventory assumptions.
Wear-time completion rate Study sessions completed at required wear time divided by planned sessions A falling rate signals comfort, fit, dryness, or workflow risk Connects to retention, reorder frequency, and clinical endpoint power.
Sensor accuracy or signal validity Valid readings divided by attempted readings; error measured against reference method Benchmark must be set by intended use and clinical standard, not by wearable-device averages Affects regulatory evidence, clinical utility, and pricing power.
Adverse event rate Reportable events divided by exposed users or wear sessions Must be tracked conservatively because eye safety drives regulatory and clinician trust Changes clinical monitoring cost, labeling, liability reserves, and adoption speed.
Clinical enrollment velocity Enrolled subjects per active site per month Slow enrollment extends burn even if direct study cost per patient is controlled Determines cash runway and timing of the next financing round.
Net revenue per active wearer Recognized lens, device, and software revenue divided by average active wearers Use channel-adjusted net revenue, not patient-facing list price Direct input to break-even active-wearer count.
Contribution margin Net revenue minus direct product, warranty, fulfillment, data, and support costs, divided by net revenue Target should rise as yield improves and purchasing volume increases Determines break-even revenue and payback speed.
Cash runway Cash balance divided by average net monthly burn For regulated development, less than 12 months of runway before a major milestone is risky Determines financing timing and negotiation leverage.
One dashboard Track safety, yield, active-wearer economics, and runway in the same operating review. Separating technical KPIs from cash KPIs hides the real risk.

The practical one-liner: if the KPI does not change a funding decision, clinical decision, manufacturing decision, or launch decision, it does not belong on the main dashboard.

Owner Earnings Are Usually Founder Salary Until Commercial Scale

Owner earnings for this business are different from owner earnings in a local service business. In the early years, the founder is usually paid a salary that investors, grant budgets, or board-approved cash plans can support. Cash distributions are uncommon because the company needs money for R&D, clinical work, manufacturing validation, regulatory submissions, inventory, and post-market support.

Once commercial revenue exists, owner income still is not the same as revenue or accounting profit. Before the founder can safely take money out, the company has to fund direct product costs, payroll, quality operations, repairs, warranty, cybersecurity maintenance, insurance, taxes, debt service, inventory growth, replacement capex, and reserves for recalls or field issues.

Owner earnings logic potential owner cash = operating profit - taxes - debt service - maintenance capex - working-capital growth - required reserves For a venture-backed device company, the answer may be zero even when the product is selling, because cash is often reinvested to expand evidence, capacity, and market access.
Commercial scenario Net revenue Gross profit assumption Operating expense Cash available before tax, debt, capex, and reserves Founder earnings interpretation
Early commercial $2.0M 45% = $900,000 $8.0M -$7.1M Founder salary only if the financing plan supports it.
Base scaling case $12.0M 58% = $7.0M $12.5M -$5.5M Cash likely reinvested; owner draw is still unlikely.
Established niche platform $35.0M 65% = $22.8M $18.0M $4.8M Owner cash may exist, but investor terms, debt, growth plans, and reserve policy come first.

This is why the model should separate founder salary, dividends, equity value, and exit proceeds. A founder may earn a market salary while the company is still unprofitable. Or the company may be profitable but still unable to distribute cash because inventory, quality, and post-market obligations consume working capital.

Existing-business profitability test For an existing smart lens operation, review contribution margin by product generation, clinical support hours per active account, complaint handling cost, warranty rate, inventory write-offs, and software maintenance. A growing revenue line can hide a product that is still too expensive to support.

What Can Go Wrong Financially?

The main risks are not abstract. They hit the forecast through redesign expense, longer runway, lower gross margin, delayed authorization, weaker adoption, higher liability reserves, and more expensive capital. The product is small, but the risk stack is large: eye safety, materials, electronics, power, wireless communication, software, clinical evidence, user comfort, and regulated manufacturing.

Manufacturing risk Low yields can turn a promising gross margin into a negative contribution margin. Model scrap, rework, retesting, and supplier qualification as separate lines.
Clinical adoption risk If clinicians do not trust the safety profile or patients dislike wear comfort, the sales ramp slows while payroll and evidence costs continue.

Connected devices also bring identity, data, and update risks. FDA's unique device identification system is designed to identify devices from manufacturing through distribution to patient use, and most devices ultimately need a UDI on labels and packages. The FDA's UDI system overview is a reminder that traceability is a cost center, not just a barcode task.

Comfort or safety issue Delays study progress, increases monitoring, and reduces active-wearer retention. Watch dropout rate, adverse events, and wear-time completion.
Poor prototype yield Raises unit cost and delays commercial inventory. Watch functional yield, scrap rate, rework, and lot acceptance.
Evidence gap Adds test cycles, consultant spend, and runway extension. Keep 10%-20% of development budget available for additional evidence work.
Workflow friction Slows prescribing and raises training cost. Watch active prescribers, time to fit, support tickets, and repeat orders.

The best financial control is stage-gating. Do not fund a broad commercial launch until the model has evidence for safety, performance, yield, clinician workflow, net revenue per user, and support cost per active account.

Opening the Business Is a Stage-Gated Financing Sequence

The opening process should be framed as capital gates rather than a checklist of tasks. Each gate should answer a financing question: did the company reduce technical risk, regulatory risk, manufacturing risk, clinical risk, or adoption risk enough to justify the next tranche of cash?

0-3 months Define intended use Lock the use case, patient group, claims, core sensor or display function, and first regulatory hypothesis.
3-9 months Prototype and IP gate Build feasibility units, file core IP, test materials, and estimate unit economics from the first bill of materials.
9-18 months Design controls and bench evidence Create design history, risk files, verification plans, early supplier controls, and preclinical test budget.
18-36 months Clinical and regulatory gate Fund IRB or IDE work if needed, run studies, prepare submission content, and validate manufacturing lots.
36-60 months Launch and scale gate Build inventory, train channels, establish UDI and complaint systems, monitor field performance, and scale capacity.

This staged view helps prevent the common mistake of raising money for a launch before proving the product is manufacturable. It also helps a founder explain why the next financing round is not just “more runway” but a specific risk-reduction milestone.

Gate 1: feasibility Spend only enough to prove the core sensing, power, comfort, or display concept can work.
Gate 2: evidence Fund bench, safety, software, and early clinical evidence that supports the intended claim.
Gate 3: manufacturability Prove yield, repeatability, traceability, packaging, and supplier controls before broad sales hiring.
Gate 4: commercial proof Measure active accounts, retention, support cost, channel margin, and reorder behavior.

Founders often use a financial model, business plan, pitch deck, and assumption tracker to keep these gates aligned. The model should not just forecast revenue. It should show what technical milestone unlocks the next capital need and what happens if that milestone slips by three, six, or twelve months.

How Is Smart Contact Lens Development Funded?

Funding usually has to be layered. Non-dilutive grants can support feasibility, but they rarely fund the whole path. Angel and seed capital can fund early prototypes and IP. Venture or strategic capital is often needed for clinical evidence, regulated manufacturing, and launch. Debt usually fits later, when collateral, contracts, inventory, or receivables exist.

For U.S. deep-technology and medical-device startups, SBIR and STTR can be important early tools. NIH explains that SBIR/STTR programs provide non-dilutive funding for early-stage R&D and lists budget guidelines for Phase I and Phase II projects, while NSF's America's Seed Fund describes up to $305,000 of Phase I funding and up to $1.25M for Phase II through its program. See the NIH SBIR/STTR funding basics and NSF's America's Seed Fund program overview for current program framing.

Founder and angel capital Best for formation, IP, feasibility prototypes, and first regulatory consultation. A practical early range is $250,000-$2.0M.
SBIR/STTR and grants Best for feasibility and translational R&D. Use grant budgets for clear technical milestones, not broad commercial spend.
Seed and Series A equity Best for design controls, bench testing, early clinical work, and pilot manufacturing. Planning rounds may run from $3.0M to $25.0M.
Strategic capital or debt Best after proof points exist. Strategic partners want IP and fit; lenders want repayment capacity, collateral, and cash-flow coverage.

SBA debt is not usually the first dollar in a high-risk medical-device R&D plan, but it can matter later. The SBA describes 7(a) as its primary business loan program, while 504 loans provide long-term fixed-rate financing for major fixed assets with maximum loan amounts listed up to $5.5 million. Use the SBA's 7(a) loan program and 504 loan program as references for debt fit, not as a substitute for equity risk capital.

Funding readiness checklist Bring investors a milestone-based use of funds, not a single total ask. Show the next evidence gate, monthly burn, runway, regulatory pathway, manufacturing yield plan, and the trigger for the following financing round.

What Payback Period Is Realistic for This Business?

Payback is difficult because early cash outflows can be large and commercial cash flow may arrive years later. A simple payback calculation is still useful, but only if the model uses cash available for payback after launch, not optimistic accounting profit. For a regulated smart lens company, payback often depends more on exit value or strategic acquisition than on early cash distributions.

Payback period formula payback period = initial investment divided by annual cash flow available for payback Use cash after direct costs, operating expense, taxes, debt service, maintenance capex, inventory growth, and required reserves. Excluding ramp-up time makes the answer look better than reality.
Payback scenario Initial invested capital Annual cash flow available for payback after scale Simple payback after cash flow turns positive Reality check
Conservative $8.0M $500,000 16.0 years May not satisfy venture investors unless strategic value is high.
Base case $12.0M $2.0M 6.0 years Add 3-5 development years before the payback clock truly starts.
Upside niche platform $20.0M $7.0M 2.9 years Requires strong margin, repeat revenue, low support cost, and fast adoption.

Payback can stretch for several reasons. Clinical timelines slip, yield improves slower than expected, the first product generation needs more support than the model assumed, channel education takes longer, and inventory has to be built before cash is collected. If the company uses debt for equipment or working capital, debt service reduces cash available for payback even when the income statement looks healthy.

Inputs Startup investment, regulatory cost, clinical cost, pilot manufacturing, and working capital.
Revenue engine Active wearers, net revenue per user, accessory revenue, software revenue, and pilot contracts.
Cash conversion Contribution margin, fixed costs, inventory, receivables, warranty, taxes, and debt service.
Payback Free cash flow or strategic exit value compared with invested capital and dilution.

The practical one-liner: do not present payback as a single number. Present a payback range tied to adoption speed, contribution margin, regulatory timing, and the number of months the company spends pre-revenue.

How Should the Financial Model Connect the Whole Business?

A useful smart contact lens financial model is an operating map. It should show how intended use drives regulatory pathway; regulatory pathway drives evidence cost; evidence cost drives runway; design maturity drives manufacturing yield; yield drives unit economics; clinician workflow drives adoption; active wearers drive recurring revenue; and cash conversion determines whether the company can survive long enough to reach scale.

Development budget Prototype cycles, testing plan, quality setup, clinical plan, and pathway selection produce the cash required to reach the next evidence gate.
Revenue and margin Active prescribers, active wearers, net revenue per user, yield, scrap, warranty, and support cost produce contribution margin by product generation.
Cash conversion Inventory days, receivable days, supplier deposits, clinical-device inventory, and warranty reserves show whether growth consumes cash.
Returns and strategy Free cash flow, debt service, taxes, dilution, and exit assumptions guide licensing, direct commercialization, or strategic partnership decisions.
The model should answer one hard question If the next milestone slips by six months, does the company still have enough cash to protect safety work, quality documentation, IP, and the core technical team? If not, the funding plan is too thin.

For a new operation, the model should focus on burn, proof points, and runway. For an existing operation, it should focus on contribution margin by product generation, post-market cost, active-wearer retention, manufacturing yield, and whether the business can fund the next product iteration without diluting owners too heavily. The economics become attractive only when evidence, adoption, manufacturing, and cash conversion reinforce each other.